Top Closed System Gaps—and Durable Fixes


Top Closed System Gaps—and Durable Fixes

Published on 29/11/2025

Top Closed System Gaps—and Durable Fixes

This article is a step-by-step tutorial guide designed to assist pharmaceutical professionals in understanding the validation of closed systems, particularly focusing on aseptic controls relevant to biologics and Advanced Therapy Medicinal Products (ATMP). As the biopharmaceutical landscape evolves, adherence to regulations from the FDA, EMA, and MHRA is critical to ensure compliance and maintain patient safety.

Understanding Closed Systems in Aseptic Production

Closed systems are integral to aseptic manufacturing, particularly in environments concerned with maintaining sterility. They are designed to minimize contamination risks when handling biological products. In this section, we will explore the concept of closed systems, their significance in aseptic practices, and potential gaps in current validation frameworks.

What are Closed Systems? Closed systems are enclosed environments that provide a controlled space for the preparation, storage, and transfer of substances without direct exposure to the external environment. The purpose of closed systems in aseptic production is to prevent microbial contamination, particularly in sensitive biological products.

Importance of Aseptic Controls: Aseptic controls, as outlined in the Aseptic Controls Annex 1, are crucial for maintaining sterility. They encompass various elements, including the design of facilities, equipment, and processes used to prevent contamination. Understanding how closed systems integrate with these aseptic controls is crucial for ensuring compliance with regulatory standards.

Regulatory Expectations

Regulations from authorities such as the FDA, EMA, and the MHRA dictate the standards and practices expected in the manufacturing of biological products. Compliance with these regulations requires robust protocols for validating closed systems. Key documents, including ICH Q5A(R2) on viral clearance, provide essential guidelines for validating these systems and ensuring effective sterilization processes.

Identifying Gaps in Closed System Validations

Despite stringent regulations, numerous gaps may exist in closed system validations. Identifying these gaps is critical for manufacturers and regulatory professionals aiming to achieve compliance and assure product safety.

  • Inadequate Viral Clearance Validation: Many facilities overlook the critical step of validating viral clearance in closed systems. This is especially true for products where the risk of virus contamination is significant. Implementing comprehensive viral clearance validation protocols, which include spiking studies, is essential.
  • Potency and Identity Control Quality Attributes: Ensuring that potency and identity CQAs are maintained within closed systems while processing biological products is vital. Failure to appropriately characterize these attributes can lead to non-compliance and risk to patient safety.
  • Chain of Identity Custody: The chain of identity custody is a crucial element in maintaining product integrity throughout the manufacturing process. Gaps in documentation or control over materials can jeopardize product safety and regulatory compliance.

Implementing Durable Fixes for Identified Gaps

After identifying potential gaps, addressing these issues with durable fixes is essential to build a compliant and reliable closed system. The following steps outline a structured approach to implementing durable solutions.

Step 1: Comprehensive Risk Assessment

Performing a thorough risk assessment should be the initial step in addressing any identified gaps. This involves evaluating each aspect of the closed system, including materials, processes, and environmental conditions. Risks associated with potential contamination, equipment failure, and operator errors should be documented and assessed. Make use of risk assessment tools such as Failure Mode and Effects Analysis (FMEA) or Risk Priority Numbers (RPN) to prioritize identified risks.

Step 2: Viral Clearance Validation and Spiking Studies

A critical component of validating closed systems is demonstrating robust viral clearance. Conduct spiking studies that simulate the viral contamination scenarios that could realistically occur during the manufacturing process.

  • Design spiking studies: Establish validation protocols that utilize spiking studies to assess the effectiveness of viral clearance methods. Confirm the suitability of the chosen method for the specific biologics being produced.
  • Analyze results: Carefully analyze the data from spiking studies to confirm that viral clearance measures meet regulatory standards. Document findings to provide evidence of compliance with guidelines set forth in ICH Q5A(R2).

Step 3: Ensuring Potency and Identity Controls

Maintaining potency and identity CQAs is vital. This requires a comprehensive approach involving regular analytical testing and characterization of biological products throughout the manufacturing lifecycle.

  • Implement analytical assays: Use robust analytical methods to evaluate potency and identity at various manufacturing stages. Ensure consistent test methods align with regulatory expectations, documenting all findings comprehensively.
  • Periodic reviews: Conduct periodic reviews of potency and identity controls to ensure that they remain valid as the production processes evolve or when introducing new products.

Step 4: Strengthening Chain of Identity Custody

A reliable chain of identity custody must be established to protect product integrity from raw material sourcing to final product delivery. Implement these practices:

  • Documentation Practices: Develop rigorous documentation practices to track materials used within the closed system. All entries must be detailed and accessible for audit purposes.
  • Employee Training: Provide regular training for all personnel involved in the manufacturing process to ensure they understand the importance of maintaining the chain of custody and adhere to best practices.

Tailoring PPQ and CPV for Advanced Therapy Medicinal Products

When dealing with ATMPs, the process performance qualification (PPQ) and continued process verification (CPV) should be tailored to meet specific product and process needs. This section will address how to effectively customize these protocols to enhance compliance and product safety.

Step 1: Understand Product-Specific Needs

Different ATMPs may have unique characteristics requiring distinct validation approaches. It is critical to understand the specific product-specific needs by reviewing:

  • Product Characteristics: Assess aspects like stability, potency, and identity CQAs, which can influence the design of PPQ and CPV activities.
  • Process Variability: Acknowledge potential process variability and adapt your validation strategy accordingly to address unique challenges associated with the product.

Step 2: Define Tailored Validation Approaches

Using the insights gained from understanding product-specific needs, define tailored validation approaches that ensure robust compliance with regulatory expectations:

  • Develop tailored PQ protocols: Customize this phase of validation to address unique elements of the ATMP, incorporating targeted approaches for risk mitigation.
  • Implement risk-based CPV methods: Establish risk-based CPV methods that allow for targeted monitoring of critical parameters throughout the product lifecycle.

Step 3: Continuous Monitoring and Adjustments

Once tailored methods are implemented, continuous monitoring is essential to ensure ongoing compliance and effectiveness.

  • 60-day review cycles: Implement review cycles to assess data collected during the CPV phase. Identify trends and make necessary adjustments to processes based on findings.
  • Regulatory compliance audits: Conduct periodic audits to confirm adherence to established protocols and maintain compliance with regulatory standards.

Conclusion

As the landscape of pharmaceutical manufacturing continues to evolve, it is critical for professionals in the field to remain vigilant in assessing and addressing gaps in the validation of closed systems. By implementing comprehensive risk assessments, robust viral clearance validation, and tailored PPQ and CPV strategies, organizations can enhance compliance while ensuring product safety and efficacy.

For further information regarding regulations and guidelines, it is advisable to refer to the documentation from the EMA and learn more about the industry’s best practices to secure safe and efficient biopharmaceutical manufacturing processes.